# Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer

> **NCT02154529** · PHASE1,PHASE2 · TERMINATED · sponsor: **Kadmon Corporation, LLC** · enrollment: 17 (actual)

## Conditions studied

- HER-2 Positive Breast Cancer
- Metastatic Malignant Neoplasm to Brain

## Interventions

- **DRUG:** Tesevatinib
- **DRUG:** Trastuzumab

## Key facts

- **NCT ID:** NCT02154529
- **Lead sponsor:** Kadmon Corporation, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-05
- **Primary completion:** 2015-09-13
- **Final completion:** 2015-09-13
- **Target enrollment:** 17 (ACTUAL)
- **Why stopped:** Sponsor closed the study due to lack of response.
- **Last updated:** 2022-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02154529

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02154529, "Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer". Retrieved via MORVS 2026-10-07 from https://api.morvs.ai/clinical/NCT02154529. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*